Cannabinoid receptor 1 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-15Cannabinoid receptor 1 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P21554. Start with obesity, then reuse UniProt P21554 as the stable protein anchor across project notes and exports.
Start with obesity, then reuse UniProt P21554 as the stable protein anchor across project notes and exports.
Cannabinoid receptor 1 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block. 6 linked drugs remain visible in the same block.
Start review with obesity because it currently carries approved-linked support. Linked drugs include IBIPINABANT, NABILONE, OTENABANT, RIMONABANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCannabinoid receptor 1
Review this target as Cannabinoid receptor 1, mapped to UniProt P21554. Sequence length is 472 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cannabinoid receptor 1 as ChEMBL target CHEMBL218, mapped to UniProt P21554. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Cannabinoid receptor 1 is the right protein anchor across sources, using UniProt P21554 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why obesity is currently framed as approved-linked support. It currently carries 6 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Cannabinoid receptor 1 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P21554 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Cannabinoid receptor 1 |
| UniProt Accession | P21554 |
| Component Type | Protein |
| Sequence Length | 472 aa |
Cannabinoid receptor 1
Review this target as Cannabinoid receptor 1, mapped to UniProt P21554. Sequence length is 472 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Cannabinoid receptor 1 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block.
Start review with obesity because it currently carries approved-linked support. Linked drugs include IBIPINABANT, NABILONE, OTENABANT, RIMONABANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4062749 | 11.0 | Ki | 0.01 | Preclinical |
| CHEMBL4847866 | 10.7 | EC50 | 0.02 | Preclinical |
| CHEMBL4873473 | 10.7 | EC50 | 0.02 | Preclinical |
| CHEMBL2063237 | 10.52 | Ki | 0.03 | Preclinical |
| CHEMBL4169198 | 10.52 | EC50 | 0.03 | Preclinical |
| CHEMBL2063236 | 10.4 | Ki | 0.04 | Preclinical |
| CHEMBL4862304 | 10.4 | EC50 | 0.04 | Preclinical |
| CHEMBL4875720 | 10.4 | EC50 | 0.04 | Preclinical |
| CHEMBL2063239 | 10.3 | Ki | 0.05 | Preclinical |
| CHEMBL4846759 | 10.3 | EC50 | 0.05 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 462 | 2,609 | 7.0 |
| single protein format | 379 | 1,335 | 7.1 |
| assay format | 40 | 459 | 6.9 |
| cell membrane format | 37 | 113 | 7.1 |
| tissue-based format | 4 | 5 | 7.1 |
| cell-free format | 1 | 10 | 5.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 373 | 1,571 | 7.2 |
| assay format | 70 | 340 | 6.5 |
| cell membrane format | 30 | 147 | 7.3 |
| single protein format | 17 | 174 | 6.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 37 | 78 | 6.3 |
| single protein format | 7 | 4 | 6.8 |
| cell membrane format | 2 | 0 | — |
| assay format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 3 | 1 | 8.2 |